Axoltis Pharma

03/23/2026 | Press release | Archived content

Bio-Europe Spring 2026

Lisbon, Portugal

23rd March 2026

Meet Axoltis Pharma at BIO-Europe Spring in Lisbon !

Yann GODFRIN, Ph.D., CEO, Nicolas REBERGUE, PhD, Project Manager will be glad to meet for partnerging discussion.

Axoltis Pharma is a phase 2 clinical stage biotech company with a head start thanks to NX210c, our product for restoring blood brain barrier integrity in neurodegenerative diseases.

SEALS is a phase 2 clinical trial evaluating efficacy of NX210c in ALS patients. The last patient has been enrolled and the topline results are expected from Q2 2026.

Axoltis Pharma published this content on March 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 09:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]